Physician profile
Morgan Schiermeier
NPI 1841552700
$1,478.24
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $852 · 2020: $189 · 2021: $27.17 · 2022: $152 · 2023: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $258.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $400.83 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $232.66 | 2019-2023 | |
| Abbvie INC. | $173.63 | 2021-2023 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $86.61 | 2019-2023 | Shingrix, Arexvy |
| Amgen INC. | $84.04 | 2019-2020 | |
| Lilly USA, LLC | $75.62 | 2019-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $71.09 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $67.40 | 2019-2020 | |
| Allergan, INC. | $65.60 | 2019-2020 | |
| Astellas Pharma US INC | $58.53 | 2019 | |
| Amarin Pharma, INC. | $50.96 | 2019-2020 | |
| Ge Healthcare | $32.18 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.70 | 2019 | |
| Abbott Laboratories | $18.53 | 2023 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.39 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $13.59 | 2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $12.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Schiermeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.